XOMA Royalty Corporation (XOMA)
NASDAQ: XOMA · Real-Time Price · USD
25.66
+0.69 (2.76%)
Jan 30, 2026, 4:00 PM EST - Market closed
XOMA Royalty Employees
XOMA Royalty had 13 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$3,623,538
Profits / Employee
$758,154
Market Cap
317.75M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 13 | 0 | - | 13 | 0 |
| Dec 31, 2023 | 13 | 0 | - | 13 | 0 |
| Dec 31, 2022 | 13 | 1 | 8.33% | 12 | 1 |
| Dec 31, 2021 | 12 | 2 | 20.00% | 12 | 0 |
| Dec 31, 2020 | 10 | 0 | - | 10 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Puma Biotechnology | 172 |
| Adlai Nortye | 123 |
| Foghorn Therapeutics | 112 |
| Rezolute | 75 |
| Larimar Therapeutics | 65 |
| Atea Pharmaceuticals | 56 |
| Immuneering | 54 |
| Cybin | 50 |
XOMA News
- 19 days ago - XOMA Royalty Announces CFO Transition - GlobeNewsWire
- 5 weeks ago - XOMA Royalty Declares Quarterly Preferred Stock Dividends - GlobeNewsWire
- 2 months ago - XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc - GlobeNewsWire
- 2 months ago - Mural Oncology Announces Sanction of the Scheme by the High Court - GlobeNewsWire
- 2 months ago - XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V. - GlobeNewsWire
- 2 months ago - XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements - GlobeNewsWire
- 3 months ago - XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement - GlobeNewsWire
- 4 months ago - XOMA Royalty PFD Update: Going Back To My Original Sell Ratings - Seeking Alpha